CellVysion

The avidity of the antibody to Natural Killer cells and tumor cells. 

We wanted to share some exciting insights from the Advanced Immunology conference in Barcelona (September 23/24, 2024), particularly reaching an optimum in the avidity of the antibody to Natural Killer (NK) cells and tumor cells.

The ability to determine the avidity of NK cells binding to cancer cells through therapeutic antibodies is a standout application of the CellVysion. This is a game-changer in selecting the most effective therapeutic antibody based on the avidity of both cell types. The antibody acts as a vital bridge, enabling optimal interaction between NK cells and cancer cells.

For companies developing bispecific antibodies, understanding cell-antibody-cell avidity is crucial. The better these bispecific antibodies function as bridges, the more effectively NK cells and other T-cells can target and eliminate cancer cells. Testing the avidity of the antibody against NK cells and tumor cells is essential for maximizing therapeutic efficacy.

Other biotech and pharmaceutical companies are leveraging various T-cell to cancer cell coupling molecules. With CellVysion, utilizing a capture gradient with CaptureSelect anti-antibodies allows for the dynamic capture of various antibodies, enabling precise measurement of cell avidity through tipping point shifts. Remarkably, the effectiveness of immunotherapy hinges on the strength of these connections, there is an optimum for the avidity, leading to higher efficacy in therapeutic applications. 

Our mission is to identify the antibody that binds to cancer cells with the perfect strength within an optimal range. The CellVysion from Vysens is designed to achieve this. Moreover, the CellVysion is a Plug & Play system and all information is available after one single run.

We developed the CellVysion with a gradient system with this purpose in mind. We are very interested to receive your opinion. Of course, if you want to carry out a pilot study with us, please contact us. Let's explore this opportunity together!

As an example we describe measuring the avidity of cells on a ligand density gradient by determining the so-called tipping point for a certain cell type - antibody combination. The tipping point is the characteristic ligand density that is just enough to capture the cells/particles under certain shear conditions. This value of avidity determined as functional Rmax value depends both on the number of receptors and the monovalent affinity per cell. Therefore, this setup and method will allow for cell-antibody avidity determination. Once we determined the tipping point, we measure the ligand density at the tipping point.

Unlocking the Future of Personalized Medicine with Vysens

At Vysens, our commitment to advancing scientific discovery and therapeutic development is embodied in our innovative technology and products.

Our flagship, the CellVysion SPR imager, is at the forefront of this mission, providing essential tools for researchers and clinicians to understand and combat diseases at the molecular level.

Empowering Research with Precision

The foundation of groundbreaking research is the ability to accurately analyze biomolecular interactions. CellVysion offers this precision through its advanced Surface Plasmon Resonance imaging (SPRi) technology, enabling scientists to dissect the complexities of cellular and antibody interactions without the need for labeling. This label-free, real-time analysis not only conserves sample integrity but also accelerates the research process, paving the way for significant advancements in various fields, including oncology, immunology, and molecular biology.

Therapeutic Applications: A New Era of Treatment

In the realm of therapeutics, the detailed insights provided by CellVysion facilitate the development of targeted treatments and personalized medicine. By understanding the specific interactions between biomolecules and cells, researchers can identify novel targets for therapy, optimize drug delivery mechanisms, and evaluate the efficacy of treatments with unprecedented accuracy. This precise characterization of molecular interactions is crucial in designing next-generation therapeutics that offer improved outcomes for patients with cancer, autoimmune diseases, and other conditions.

Advancing Drug Discovery and Development

CellVysion accelerates the drug discovery process by enabling the rapid screening of potential therapeutic candidates. Its ability to measure both affinity and concentration in a single experiment reduces development time and costs, allowing for a more efficient path from laboratory research to clinical trials. Furthermore, the detailed data generated by CellVysion supports the rigorous validation of drug candidates, ensuring that only the most promising therapies advance towards regulatory approval and clinical use.

Collaboration for Innovation

Vysens is dedicated to fostering collaborations across the scientific community. By partnering with research institutions, pharmaceutical companies, and clinicians, we aim to leverage the full potential of SPR technology in uncovering new therapeutic avenues and advancing patient care. Our technology serves as a bridge between basic research and clinical applications, contributing to the global effort to combat diseases and improve health outcomes.

Join Us in Shaping the Future

We invite researchers and clinicians to explore the possibilities offered by CellVysion and join us in the pursuit of innovative solutions for tomorrow's therapeutic challenges. Together, we can unlock new frontiers in personalized medicine and transform the landscape of healthcare.

Network & ordering information

Our intention is to set up a network for the development of applications with our instruments. Therefore, we invite you to send us feedback. Either via LinkedIn or via our Contactform on this website.